Figure 1




Figure 2




Figure 3




Figure 4



Ingredient
Process Step
Emtricitabine
Tenofovir DF
Pregelatinized Starch
Lactose Monohydrate
Microcrystalline Cellulose
Croscarmellose Sodium
Blending
Purified Water
Wet Granulation
Wet Milling
Drying
Dry Milling
Croscarmellose Sodium
Blending
Magnesium Stearate
Blending
Layer 1
Ingredient
Process Step
Rilpivirine HCl
Lactose Monohydrate
Croscarmellose Sodium
Blending
Povidone
Polysorbate 20
Purified Water
Fluid Bed Granulation
Drying
Size Reduction
Lactose Monohydrate
Microcrystalline Cellulose
Croscarmellose Sodium
Blending
Magnesium Stearate
Blending
Layer 2
Bilayer Compression
Opadry II Purple 33G100000
Purified Water
Film-Coating
Packaging

Figure 5



Ingredient
Process Step
Ingredient
Process Step
Emtricitabine
Tenofovir DF
Pregelatinized Starch
Lactose Monohydrate
Microcrystalline Cellulose
Croscarmellose Sodium
Blending
Rilpivirine HCl
Lactose Monohydrate
Croscarmellose Sodium
Blending
Purified Water
Wet Granulation
Povidone
Polysorbate 20
Purified Water
Fluid Bed Granulation
Wet Milling
Drying
Drying
Size Reduction
Dry Milling
Lactose Monohydrate
Microcrystalline Cellulose
Croscarmellose Sodium
Blending
Croscarmellose Sodium
Blending
Magnesium Stearate
Blending
Magnesium Stearate
Blending
Trilayer Compression
Lactose Monohydrate
Opadry II Purple 33G100000
Purified Water
Film-Coating
Packaging

Figure 6



Ingredient
Process Step
Emtricitabine
Tenofovir DF
Pregelatinized Starch
Lactose Monohydrate
Microcrystalline Cellulose
Croscarmellose Sodium
Blending
Purified Water
Wet Granulation
Wet Milling
Drying
Dry Milling
Croscarmellose Sodium
Blending
Magnesium Stearate
Blending
Compression
Rilpivirine HCl
Povidone
Lactose Monohydrate
Purified Water
Film-Coating
Packaging

Figure 7



Co-Granulation 1 (3639-182)
Co-Granulation 2 (3639-183)
Co-Granulation 3 (3866-1)
Co-Granulation 4 (3866-2)
Co-Granulation 5 (3866-22)
Truvada Tablets
% Total TDF Impurities and Degradants
Time (weeks)
Truvada Tablets
0
1
2
3
4
5
6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5

Figure 8




% Total TDF Impurities and Degradants
0
1
2
3
4
5
6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Time (weeks)
Formulation 1
Formulation 2
Truvada Tablets

Figure 9


100
80
60
40
20
0
% RPV Dissolved
0% CCS
25% CCS
50% CCS
75% CCS
200% CCS
0
15
30
45
60
75
90
105
120
Time (min)